Knowing this cut-off value likely to result in haemolysis enables the treatment of some G6PD heterozygous women who would be likely to tolerate primaquine or tafenoquine therapy for malaria who otherwise might have been excluded because of their heterozygosity. The gene discussed is G6PD; the disease is malaria.